Bryon D. Johnson, PhD

Professor, Pediatrics (Hematology/Oncology/BMT) and Microbiology & Immunology

Locations

Microbiology & Immunology

Contact Information

General Interests

Cancer immunology and immunotherapy

Education

PhD, Immunology, University of Health Sciences/The Chicago Medical School (now Rosalind Franklin University), 1989
BS, Microbiology, Iowa State University, 1983

Research Interests

I am interested in understanding the biology and immunology of cancer, and uncovering novel immune-based approaches to treat cancer. My current research focuses on combining the following approaches to improve the use of cancer immunotherapy for treating both solid tumors and hematologic cancers: (1) immune checkpoint protein blockade, (2) adoptive transfer of cancer-reactive T lymphocytes, and (3) the use of metabolic inhibitors to increase T cell immunity.

Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.

(Shah NN, Colina AS, Johnson BD, Szabo A, Furqan F, Kearl T, Schneider D, Vargas-Cortes M, Schmeling JL, Dwinell MB, Palen K, Longo W, Hematti P, Zamora AE, Hari P, Bucklan D, Cunningham A, Hamadani M, Fenske TS.) J Clin Oncol. 2025 Mar 31:JCO2402158 PMID: 40163793 03/31/2025
Platelet-Targeted Gene Therapy for Hemophilia A with Inhibitor History.

(Eapen M, Malec LM, Armant MA, Johnson BD, Shi Q, Xu H, Du LM, Jerkins JH, Duffy LJ, Bushman FD, Lee C, Petrichenko A, Hematti P, Brazauskas R, Jobe SM, Hari PN, Wilcox DA.) N Engl J Med. 2025 Jan 23;392(4):412-414 PMID: 39842018 PMCID: PMC11756741 SCOPUS ID: 2-s2.0-85216608254 01/22/2025
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.

(Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D.) Clin Cancer Res. 2023 Dec 01;29(23):4784-4796 PMID: 37463058 PMCID: PMC10690096 SCOPUS ID: 2-s2.0-85178651085 07/18/2023
Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes.

(Chu Y, Milner J, Lamb M, Maryamchik E, Rigot O, Ayello J, Harrison L, Shaw R, Behbehani GK, Mardis ER, Miller K, Prakruthi Rao Venkata L, Chang H, Lee D, Rosenthal E, Kadauke S, Bunin N, Talano JA, Johnson B, Wang Y, Cairo MS.) J Infect Dis. 2023 Mar 28;227(6):788-799 PMID: 36583990 SCOPUS ID: 2-s2.0-85151044080 12/31/2022
Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes.

(Knight JM, Hackett E, Szabo A, Wu R, Sauber G, Johnson B, Cusatis RN, Aughey E, Cole SW, Hillard CJ, Shah NN.) Haematologica. 2023 Feb 01;108(2):588-593 PMID: 36200427 PMCID: PMC9890001 SCOPUS ID: 2-s2.0-85147234722 10/07/2022
Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention.

(Pan J, Xiong D, Zhang Q, Palen K, Shoemaker RH, Johnson B, Sei S, Wang Y, You M.) Front Immunol. 2023;14:1036563 PMID: 36875137 PMCID: PMC9982083 SCOPUS ID: 2-s2.0-85149504680 03/07/2023
Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells.

(Zurko JC, Fenske TS, Johnson BD, Bucklan D, Szabo A, Xu H, Chaney K, Hamadani M, Hari P, Shah NN.) Am J Hematol. 2022 Dec;97(12):1580-1588 PMID: 36068950 SCOPUS ID: 2-s2.0-85138335080 09/08/2022
The effect of tocilizumab on patient reported outcomes and inflammatory biomarkers in hematopoietic cell transplantation.

(Taylor MR, Hillard CJ, Drobyski WR, Szabo A, Johnson BD, Zhu F, Raison CL, Cole SW, Knight JM.) Brain Behav Immun Health. 2022 Aug;23:100480 PMID: 35757656 PMCID: PMC9213229 SCOPUS ID: 2-s2.0-85133379996 06/28/2022
Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies.

(Zurko JC, Xu H, Chaney K, Schneider D, Szabo A, Hari P, Johnson BD, Shah NN.) Cytotherapy. 2022 Aug;24(8):767-773 PMID: 35597752 SCOPUS ID: 2-s2.0-85130432792 05/22/2022
Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome.

(Zurko JC, Johnson BD, Aschenbrenner E, Fenske TS, Hamadani M, Hari P, Shah NN.) JAMA Oncol. 2022 May 01;8(5):773-775 PMID: 35266965 PMCID: PMC8914887 SCOPUS ID: 2-s2.0-85126591538 03/11/2022
Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria-Targeted Atovaquone.

(Huang M, Xiong D, Pan J, Zhang Q, Wang Y, Myers CR, Johnson BD, Hardy M, Kalyanaraman B, You M.) Adv Sci (Weinh). 2022 Apr;9(12):e2101267 PMID: 35243806 PMCID: PMC9036031 SCOPUS ID: 2-s2.0-85125564839 03/05/2022
Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease.

(Chu Y, Talano JA, Baxter-Lowe LA, Verbsky JW, Morris E, Mahanti H, Ayello J, Keever-Taylor C, Johnson B, Weinberg RS, Shi Q, Moore TB, Fabricatore S, Grossman B, van de Ven C, Shenoy S, Cairo MS.) Front Immunol. 2022;13:1055497 PMID: 36569951 PMCID: PMC9780682 SCOPUS ID: 2-s2.0-85144637382 12/27/2022